Abstract
Cerebral vasospasm is a common and serious complication of aneurysmal subarachnoid haemorrhage (SAH). At present, no consistently effective preventative and therapeutic measures are available, perhaps because of incomplete understanding of the pathogenesis of vasospasm. Experimental studies provide evidence that the incidence and severity of vasospasm after SAH can be modulated by drugs that affect neurotransmitter levels, intracellular signalling mechanisms, vascular smooth muscle function, inflammation and cellular proliferation, and the concentration of 'spasmogenic' factors. Preliminary clinical studies indicate that some illicit drugs and common prescription medications can have similar effects in humans. Recognition of these pharmacological effects is important because medications that can worsen or alleviate vasospasm are frequently administered to SAH patients to treat coincident medical problems.
MeSH terms
-
Angiotensin-Converting Enzyme Inhibitors / adverse effects
-
Angiotensin-Converting Enzyme Inhibitors / therapeutic use
-
Anti-Inflammatory Agents, Non-Steroidal / adverse effects
-
Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
-
Antidepressive Agents / adverse effects
-
Antidepressive Agents / therapeutic use
-
Calcium Channel Blockers / adverse effects
-
Calcium Channel Blockers / therapeutic use
-
Humans
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors / adverse effects
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
-
Nitric Oxide Donors / adverse effects
-
Nitric Oxide Donors / therapeutic use
-
Prevalence
-
Risk Assessment
-
Risk Factors
-
Subarachnoid Hemorrhage / complications*
-
Vasospasm, Intracranial / chemically induced*
-
Vasospasm, Intracranial / drug therapy*
-
Vasospasm, Intracranial / epidemiology
Substances
-
Angiotensin-Converting Enzyme Inhibitors
-
Anti-Inflammatory Agents, Non-Steroidal
-
Antidepressive Agents
-
Calcium Channel Blockers
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors
-
Nitric Oxide Donors